Search results
GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims
Benzinga via Yahoo Finance· 4 days agoGSK Plc (NYSE:GSK) has been reportedly sued by an independent Connecticut laboratory, Valisure,...
Independent Advisor Alliance Has $740,000 Position in GSK plc (NYSE:GSK)
ETF DAILY NEWS· 5 days agoIndependent Advisor Alliance decreased its position in GSK plc (NYSE:GSK – Free Report) by 8.9% in the 4th quarter, according to the company in its most ...
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
Barrons.com· 2 days agoThe American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual...
GSK’s New Vaccine Kept the Boss in Her Job — and an Activist at Bay
Bloomberg via Yahoo Finance· 5 days ago(Bloomberg) -- When Elliott Investment Management came calling for the ouster of Emma Walmsley, the...
GSK faces whistleblower lawsuit over Zantac cancer risk | Honolulu Star-Advertiser
Honolulu Star-Advertiser· 6 days agoGSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding...
GSK’s asthma drug shows promise in reducing severe attacks
WHTC 1450 Holland· 5 days ago(Reuters) - GSK's asthma drug met its primary goal of reducing asthma attacks over a 52-week period...
GSK says late-stage trials of potential blockbuster asthma drug met their goals
Market Watch· 5 days agoGSK on Tuesday said two late-stage trials of an asthma drug that could have peak sales of more than...
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
Zacks via Yahoo Finance· 4 days agoGSK’s GSK two-phase III studies, which evaluated depemokimab for treating severe asthma...
GSK Faces Whistleblower Suit From Lab That Found Zantac Risk
Insurance Journal· 5 days agoGSK Plc is facing a whistleblower lawsuit that could potentially cost it billions of dollars from...
Q3 2024 EPS Estimates for GSK plc Boosted by Zacks Research (NYSE:GSK)
ETF DAILY NEWS· 2 days agoGSK plc (NYSE:GSK – Free Report) – Analysts at Zacks Research increased their Q3 2024 earnings estimates for shares of GSK in a note ...